Biogen MS drug scripts up 12% in week eight, says Citigroup
Citigroup says that in its eighth week of launch, scripts for Biogen's (BIIB) multiple sclerosis drug Tecfidera were up 12% to 2,203.
Citi notes it took 54 weeks for Novartis' Gilenya to reach that scrip level. The firm says Tecfidera is set to beat Q2 and 2013 estimates by a large amount and it keeps a Buy rating on shares of Biogen.
Market Data 
Markets 
AI
